Welcome Holger Müller – Director of Business Development at Disruptive Pharma

Holger brings more than 20 years of experience in commercialization of pharmaceutical products and innovations, from early phases up to commercial launch and product lifecycle management. Holger is an experienced c-level executive in innovation driven companies, with an established track-record of turning scientific innovations into marketable products and has experience from various management roles in BigPharma, strategy consulting firm and start-ups (e.g. Novartis Pharma AG, Health Advances GmbH, Athenex, and others). Holger has a PhD in chemistry from ETH, Zürich, Switzerland and a CFA from Chartered Financial Institute, Charlottesville, USA. Welcome to our team Holger, we are so glad to have you onboard! #disruptivepharma

Welcome Malin Vågerö – Director R&D at Disruptive Pharma

As an excellent addition to team Disruptive Pharma we are now happy to announce Malin Vågerö as our Director R&D. Malin brings more than 25 years of experience in drug development in large and small companies, from early phase to commercial launch and product maintenance. 20 years of experience in various management roles (AstraZeneca, Nanologica AB, APL). Malin has BSc in chemistry from Stockholm University and among many of her talents she is also a dedicated golf player! We welcome Malin Vågerö to the team, we are so happy to have you onboard! #disruptivepharma

Disruptive Pharma raises 41 million SEK to develop pipeline project towards clinical stage

We have some exciting news to share just before the summer – Disruptive ...